Clinical and biological features of favorable-risk acute myelogenous leukemia--is favorable-risk AML really favorable?
Schiller
G J
GJ
Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095-3075, USA. garyjs@ucla.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D015996:Survival Rate